Brokerages Set Fresenius Medical Care AG (NYSE:FMS) Target Price at $24.00

Fresenius Medical Care AG (NYSE:FMS) has earned a consensus rating of “Hold” from the seven analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $24.00.

A number of brokerages have commented on FMS. StockNews.com began coverage on shares of Fresenius Medical Care in a research note on Tuesday. They set a “strong-buy” rating for the company. Truist Financial raised their price target on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a research note on Wednesday, May 15th.

Fresenius Medical Care Stock Down 1.4 %

FMS stock opened at $19.25 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.50 and a quick ratio of 1.14. Fresenius Medical Care has a 52-week low of $16.37 and a 52-week high of $27.72. The company has a 50-day moving average of $20.84 and a two-hundred day moving average of $20.22. The stock has a market capitalization of $11.29 billion, a price-to-earnings ratio of 21.62, a price-to-earnings-growth ratio of 1.03 and a beta of 0.93.

Fresenius Medical Care (NYSE:FMS) last released its earnings results on Tuesday, May 7th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.10. Fresenius Medical Care had a net margin of 2.48% and a return on equity of 5.29%. The business had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.15 billion. As a group, equities research analysts anticipate that Fresenius Medical Care will post 1.5 EPS for the current year.

Fresenius Medical Care Cuts Dividend

The company also recently disclosed an annual dividend, which was paid on Monday, June 3rd. Stockholders of record on Monday, May 20th were issued a dividend of $0.437 per share. This represents a dividend yield of 2.35%. The ex-dividend date of this dividend was Friday, May 17th. Fresenius Medical Care’s payout ratio is 49.44%.

Institutional Trading of Fresenius Medical Care

Several hedge funds have recently modified their holdings of the company. Morningstar Investment Services LLC increased its holdings in shares of Fresenius Medical Care by 6.4% during the third quarter. Morningstar Investment Services LLC now owns 10,145 shares of the company’s stock worth $220,000 after buying an additional 612 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Fresenius Medical Care by 21.8% during the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock worth $82,000 after buying an additional 758 shares in the last quarter. Hartford Financial Management Inc. increased its holdings in shares of Fresenius Medical Care by 98.8% in the fourth quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock valued at $35,000 after purchasing an additional 839 shares in the last quarter. Raymond James & Associates increased its holdings in shares of Fresenius Medical Care by 4.0% in the fourth quarter. Raymond James & Associates now owns 28,960 shares of the company’s stock valued at $603,000 after purchasing an additional 1,125 shares in the last quarter. Finally, Bruce G. Allen Investments LLC acquired a new stake in shares of Fresenius Medical Care in the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.